Last reviewed · How we verify
Rhinol (TRAMAZOLINE)
Rhinol (generic name: TRAMAZOLINE) is a tramazoline drug. It is currently in Phase 2 development for Allergic conjunctivitis, Allergic rhinitis, Common cold.
Rhinol works by activating the alpha-2A adrenergic receptor to constrict blood vessels in the nasal passages.
Rhinol (Tramazoline) is a small molecule drug that targets the alpha-2A adrenergic receptor. It is used to treat various nasal and respiratory conditions, including allergic conjunctivitis, allergic rhinitis, and common cold symptoms. The commercial status of Rhinol is unknown, and it is not clear if it is patented or available as a generic medication. Key safety considerations include potential side effects such as dry mouth, dizziness, and headache. As a vasoconstrictor, Rhinol works by narrowing blood vessels in the nasal passages to reduce congestion and discharge.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | TRAMAZOLINE |
|---|---|
| Drug class | tramazoline |
| Target | Alpha-2A adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | Phase 2 |
Mechanism of action
Imagine your nasal passages are like a busy highway. When you're congested, the traffic is backed up and it's hard to breathe. Rhinol helps by narrowing the road, allowing the traffic to flow more easily and reducing congestion.
Approved indications
- Allergic conjunctivitis
- Allergic rhinitis
- Common cold
- Nasal congestion
- Nasal discharge
- Seasonal allergic rhinitis
- Sneezing
- Vasomotor rhinitis
Common side effects
Key clinical trials
- Treatment With Rhinospray Plus in Patients With Acute Rhinitis in the Everyday Curative Routine in Hungary
- Nasal Tramazoline and Dexamethazone in Obstructive Sleep Apnea (OSA) Patients Tramazoline and (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rhinol CI brief — competitive landscape report
- Rhinol updates RSS · CI watch RSS
Frequently asked questions about Rhinol
What is Rhinol?
How does Rhinol work?
What is Rhinol used for?
What is the generic name of Rhinol?
What drug class is Rhinol in?
What development phase is Rhinol in?
What does Rhinol target?
Related
- Drug class: All tramazoline drugs
- Target: All drugs targeting Alpha-2A adrenergic receptor
- Therapeutic area: All drugs in Hematology
- Indication: Drugs for Allergic conjunctivitis
- Indication: Drugs for Allergic rhinitis
- Indication: Drugs for Common cold
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing